 AUSTIN, Texas--BUSINESS WIRE--Savara Inc. Nasdaq: SVRA, a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that on May 11, 2021, the Compensation Committee of the Companys Board of Directors granted a newly hired employee the option to purchase 175,000 shares of the Companys common stock and restricted stock units RSUs covering 100,000 shares of the Companys common stock. These equity awards were granted pursuant to Rule 5635c4 of the N 